I agree that this site is using cookies. You can find further informations here.
X
Nicolas Roussot
26  results:
Search for persons X
?
1

Effect of radiochemotherapy on peripheral immune response i..:

Hampe, Léa ; Daumoine, Susy ; Limagne, Emeric...
Cancer Immunology, Immunotherapy.  73 (2024)  7 - p. , 2024
Link: https://doi.org/10.1007/..
 
?
2

Prognostic stratification ability of the CPS+EG scoring sys..:

Roussot, Nicolas ; Constantin, Guillaume ; Desmoulins, Isabelle...
European Journal of Cancer.  202 (2024)  - p. 114037 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Clinical Utility of Genomic Tests Evaluating Homologous Rec..:

Galland, Loïck ; Roussot, Nicolas ; Desmoulins, Isabelle...
Cancers.  15 (2023)  4 - p. 1299 , 2023
Link: https://doi.org/10.3390/..
 
?
4

FGF/FGFR genomic amplification as a predictive biomarker fo..:

Roussot, Nicolas ; Lecuelle, Julie ; Dalens, Lorraine..
Journal for ImmunoTherapy of Cancer.  11 (2023)  10 - p. e007763 , 2023
Link: https://doi.org/10.1136/..
 
?
5

Pathologic complete response and survival in HER2-low and H..:

Ilie, Silvia Mihaela ; Briot, Nathalie ; Constantin, Guillaume...
Breast Cancer.  30 (2023)  6 - p. 997-1007 , 2023
Link: https://doi.org/10.1007/..
 
?
6

A phase I study of the combination of atezolizumab, tiragol..:

Roussot, Nicolas ; Fumet, Jean-David ; Limagne, Emeric...
BMC Cancer.  23 (2023)  1 - p. , 2023
Link: https://doi.org/10.1186/..
 
?
7

FOLFIRI-bevacizumab as a second-line treatment for advanced..:

Roussot, Nicolas ; Vincent, Julie ; Palmier, Remi...
Frontiers in Oncology.  13 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
8

Tumor Immunogenic Cell Death as a Mediator of Intratumor CD..:

Roussot, Nicolas ; Ghiringhelli, François ; Rébé, Cédric
Cells.  11 (2022)  22 - p. 3672 , 2022
Link: https://doi.org/10.3390/..
 
?
9

Image_2_FOLFIRI-bevacizumab as a second-line treatment for ..:

Nicolas Roussot ; Julie Vincent ; Remi Palmier...
doi:10.3389/fonc.2023.1293670.s002.  , 2023
Link: https://doi.org/10.3389/..
 
?
10

Image_2_FOLFIRI-bevacizumab as a second-line treatment for ..:

Nicolas Roussot ; Julie Vincent ; Remi Palmier...
doi:10.3389/fonc.2023.1293670.s002.  , 2023
Link: https://doi.org/10.3389/..
 
?
11

Additional file 1 of A phase I study of the combination of ..:

Nicolas Roussot ; Jean-David Fumet ; Emeric Limagne...
doi:10.6084/m9.figshare.24540556.v1.  , 2023
Link: https://doi.org/10.6084/..
 
?
12

Image_1_FOLFIRI-bevacizumab as a second-line treatment for ..:

Nicolas Roussot ; Julie Vincent ; Remi Palmier...
doi:10.3389/fonc.2023.1293670.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
13

Image_3_FOLFIRI-bevacizumab as a second-line treatment for ..:

Nicolas Roussot ; Julie Vincent ; Remi Palmier...
doi:10.3389/fonc.2023.1293670.s003.  , 2023
Link: https://doi.org/10.3389/..
 
?
14

Clinical Utility of Genomic Tests Evaluating Homologous Rec..:

Loïck Galland ; Nicolas Roussot ; Isabelle Desmoulins...
https://www.mdpi.com/2072-6694/15/4/1299.  , 2023
Link: https://doi.org/10.3390/..
 
?
15

Image_3_FOLFIRI-bevacizumab as a second-line treatment for ..:

Nicolas Roussot ; Julie Vincent ; Remi Palmier...
doi:10.3389/fonc.2023.1293670.s003.  , 2023
Link: https://doi.org/10.3389/..
 
1-15